Topical administration of a doxorubicin-specific monoclonal antibody prevents drug-induced mouth apoptosis in mice.

Abstract

One of the most severe side effects of anti-tumour chemotherapy is mucositis due to drug toxicity for rapidly dividing cells. We show here that anti-DXR monoclonal antibodies can prevent DXR-induced damage. Indeed, apoptosis, confined to the proliferative compartment of the basal mucosa, observed in the tongue of DXR-treated mice was completely inhibited by topical application of the anti-DXR antibodies.

• Authors: A Balsari, C Rumio, D Morelli, L Sfondrini, E Nardini, I Barajon, S Ménard
• Journal: British journal of cancer (Br J Cancer) Vol. 85 Issue 12 Pg. 1964-7 (Dec 14 2001) ISSN: 0007-0920 [Print] England
• PMID: 11747341 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibiotics, Antineoplastic
• Antibodies, Monoclonal
• Doxorubicin

Topics

• Administration, Topical
• Animals
• Antibiotics, Antineoplastic (immunology, toxicity)
• Antibodies, Monoclonal (administration & dosage, immunology, therapeutic use)
• Antibody Specificity
• Apoptosis (drug effects)
• Doxorubicin (immunology, toxicity)
• Drug Evaluation, Preclinical
• Female
• Glossitis (chemically induced, pathology, prevention & control)
• Humans
• Mice
• Mice, Inbred BALB C
• Mouth Mucosa (drug effects, pathology)
• Stomatitis (chemically induced, pathology, prevention & control)
• Tongue (drug effects, pathology)